Newsfeeds - Spark Newswire

1 minute read

Theravance Biopharma To Sell TRELEGY ELLIPTA Royalty Interests To Royalty Pharma for ~$1.1B In Upfront Cash With Over $1.5B In Potential Total Value

Today, 4:20 PM

Over $1.5 Billion in Potential Total Value, Including Approximately $1.1 Billion in Upfront Cash, up to $250 Million in Sales-Based Milestone Payments and an Estimated NPV

RPRX

10 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For May 23, 2022

By Benzinga Insights

Today, 4:20 PM

ABBV

1 minute read

SVB Leerink Initiates Coverage On Theravance Biopharma with Outperform Rating, Announces Price Target of $12

By Benzinga Newsdesk

Today, 4:20 PM

SVB Leerink analyst David Risinger initiates coverage on Theravance Biopharma (NASDAQ:TBPH) with a Outperform rating and announces Price Target of $12.

TBPH

30 minute read

Earnings Scheduled For May 5, 2022

By Benzinga Insights

Today, 4:20 PM

Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.

AAOI

1 minute read

Earnings

Theravance Biopharma’s Earnings Outlook

By Benzinga Insights

Today, 4:20 PM

Theravance Biopharma (NASDAQ:TBPH) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Theravance Biopharma will report an earnings per share (EPS) of $-0.11.

TBPH

1 minute read

Why Theravance Biopharma Stock Is Trading Lower After Hours

By Adam Eckert

Today, 4:20 PM

Theravance Biopharma Inc (NASDAQ: TBPH) shares are trading lower in Monday's after-hours session after the company announced the results from Study 0170 showed the primary endpoint was not statistically significant for the overall population of patients.

TBPH

1 minute read

HC Wainwright & Co. Maintains Buy on Theravance Biopharma, Raises Price Target to $12

By Benzinga Newsdesk

Today, 4:20 PM

HC Wainwright & Co. analyst Douglas Tsao maintains Theravance Biopharma (NASDAQ:TBPH) with a Buy and raises the price target from $8 to $12.

TBPH

1 minute read

Recap: Theravance Biopharma Q4 Earnings

By Benzinga Insights

Today, 4:20 PM

Theravance Biopharma (NASDAQ:TBPH) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

TBPH